Bauer Stefan, Hangel Doris, Yu Philipp
Institut für Immunologie, Philipps-Universität Marburg, BMFZ, Hans-Meerweinstr. 2, 35043 Marburg, Germany.
Immunobiology. 2007;212(6):521-33. doi: 10.1016/j.imbio.2007.03.011. Epub 2007 Apr 27.
Allergic diseases prevalence rates have increased dramatically over the last 50 years in developed countries and one explanation might be that modern practices in public health lead to a decreased exposure towards pathogens resulting in a misguided immune response. Recently, it has become evident that immune responses against pathogens are initiated by Toll-like receptors (TLRs) that recognize a variety of structures derived from viruses, bacteria, fungi or protozoa. In this review we will discuss TLR ligands, TLR signaling in regard to Th1 and Th2 immune responses, their involvement in the development and their therapeutic potential in treatment of allergic disease.
在过去50年里，发达国家过敏性疾病的患病率急剧上升，一种解释可能是现代公共卫生措施导致人们接触病原体的机会减少，从而引发了错误的免疫反应。最近，有证据表明，针对病原体的免疫反应是由Toll样受体（TLR）启动的，这些受体能够识别来自病毒、细菌、真菌或原生动物的多种结构。在这篇综述中，我们将讨论TLR配体、TLR在Th1和Th2免疫反应方面的信号传导、它们在过敏性疾病发展中的作用以及它们在治疗过敏性疾病方面的潜在治疗价值。
